MedTrace Logo

CMV IGG Antibodies in Semen as a Predictor for Blood Testis Barrier Damage

NCT05302856 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2022-08-23

No results posted yet for this study

Summary

To assess whether the presence of Cytomegalovirus (CMV) Immunoglobulin G (IGG) antibodies in semen is a reliable predictor of male subfertility or infertility.

Conditions

  • Male Infertility

Interventions

DIAGNOSTIC_TEST

Blood test (CMV IGG, Anti sperm antibody, Testosterone levels)

Peripheric blood extraction

Sponsors & Collaborators

  • Hadassah Medical Organization

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-03-02
Primary Completion
2023-03-31
Completion
2023-03-31

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05302856 on ClinicalTrials.gov